Aarti Drugs Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Prakash Patil
Algemeen directeur
₹27.8m
Totale compensatie
| Percentage CEO-salaris | 41.5% |
| Dienstverband CEO | 39.8yrs |
| Eigendom CEO | 9.6% |
| Management gemiddelde ambtstermijn | 11.3yrs |
| Gemiddelde ambtstermijn bestuur | 8.3yrs |
Recente managementupdates
Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)
Oct 11Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹2b |
| Jun 30 2024 | n/a | n/a | ₹2b |
| Mar 31 2024 | ₹28m | ₹12m | ₹2b |
| Dec 31 2023 | n/a | n/a | ₹2b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | n/a | n/a | ₹2b |
| Mar 31 2023 | ₹28m | ₹11m | ₹2b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹31m | ₹10m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹2b |
| Mar 31 2021 | ₹35m | ₹8m | ₹3b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹2b |
| Mar 31 2020 | ₹19m | ₹7m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹1b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹888m |
| Mar 31 2019 | ₹15m | ₹7m | ₹898m |
| Dec 31 2018 | n/a | n/a | ₹863m |
| Sep 30 2018 | n/a | n/a | ₹887m |
| Jun 30 2018 | n/a | n/a | ₹943m |
| Mar 31 2018 | ₹14m | ₹7m | ₹823m |
Compensatie versus markt: De totale vergoeding ($USD 331.17K ) Prakash } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 268.55K ).
Compensatie versus inkomsten: De vergoeding van Prakash is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Prakash Patil (77 yo)
39.8yrs
Tenure
₹27,848,000
Compensatie
Mr. Prakash Moreshwar Patil has been the Chairman of the Board of Aarti Drugs Limited since April 2014. Mr. Patil has been the Managing Director of Aarti Drugs Limited since June 1, 2007 and serves as its...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | no data | ₹27.85m | 9.59% ₹ 4.3b | |
| Joint MD & Executive Director | 21.6yrs | ₹25.54m | 4.71% ₹ 2.1b | |
| CFO & COO | 12.3yrs | ₹11.44m | 1.23% ₹ 552.1m | |
| Company Secretary & Compliance Officer | 5.6yrs | ₹1.17m | geen gegevens | |
| Whole-Time Director | no data | ₹25.54m | 4.43% ₹ 2.0b | |
| Whole-Time Director | 24.1yrs | ₹3.35m | 0.055% ₹ 24.5m | |
| MD & Executive Director | 10.2yrs | ₹25.54m | 4.61% ₹ 2.1b | |
| Vice President of Technical | no data | geen gegevens | geen gegevens | |
| Managing Director of the Pinnacle Life Science Private Limited | less than a year | geen gegevens | 1.02% ₹ 458.3m |
11.3yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AARTIDRUGS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 39.8yrs | ₹27.85m | 9.59% ₹ 4.3b | |
| Joint MD & Executive Director | 37.8yrs | ₹25.54m | 4.71% ₹ 2.1b | |
| Whole-Time Director | 29.2yrs | ₹25.54m | 4.43% ₹ 2.0b | |
| Whole-Time Director | 24.1yrs | ₹3.35m | 0.055% ₹ 24.5m | |
| MD & Executive Director | 12.3yrs | ₹25.54m | 4.61% ₹ 2.1b | |
| Chairman Emeritus | 12.3yrs | ₹43.00k | 1.86% ₹ 833.8m | |
| Independent Director | 2.5yrs | ₹155.00k | geen gegevens | |
| Additional Independent Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Director | 4.3yrs | ₹100.00k | geen gegevens | |
| Independent Director | 3.1yrs | ₹215.00k | geen gegevens | |
| Independent Director | 2.5yrs | ₹155.00k | geen gegevens | |
| Additional Independent Director | less than a year | geen gegevens | geen gegevens |
8.3yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AARTIDRUGS wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).